193 results
Thumbnail

D2.258 - Fixed drug eruption caused by co-amoxiclav

Thumbnail

D2.266 - Four-Year Analysis of the Incidence and Clinical Features of Perioperative Hypersensitivity Reactions in the Allergy-Anaesthesia Unit, Universitary Hospital Cruz Roja

Thumbnail

D2.273 - Kratom-induced anaphylaxis revealed Monoclonal Mast Cells of Clinical Significance

Thumbnail

D2.274 - Incidence of Perioperative Hypersensitivity Reactions in Spanish hospitals group. Three years of study 2022 to 2024

Thumbnail

D2.278 - National Survey on Perioperative Hypersensitivity Reactions: Evaluating Practices and Challenges in Spanish Hospitals

Thumbnail

D2.287 - Evaluation of NSAID Hypersensitivity in Children: A Retrospective Analysis

Thumbnail

D2.288 - Idursulfase Hypersensitivity Reactions: Unpacking Immunological Mechanisms Beyond Clinical Manifestations

Thumbnail

D2.289 - A Cardiovascular Enigma in the Emergency Room

Thumbnail

D1.34 - Hypersensitivity Reactions to Iodinated and Gadolinium-Based Contrast Media: Clinical and Epidemiological Insights

Thumbnail

D1.37 - Sometimes it is not what it seems

Thumbnail

D1.248 - Perioperative hypersensitivity reaction (POH) with tranexamic acid: study of 2 cases

Thumbnail

D1.249 - Improving inpatient antimicrobial stewardship through single dose oral amoxicillin challenge among penicillin allergic veterans

Thumbnail

000766 - Clonal mast cell disorders, allergy to hymenoptera venom and venom immunotherapy – our experience

Thumbnail

- D3.117 - Targeting Mast Cells with Briquilimab, an Anti-Human c-Kit (CD117) Antibody, Mitigates COPD-Like Features in an Allergen and Cigarette Smoke-Exacerbated Asthma Model Using Humanized h/mCD117 Mice

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.204 - Elevated Tryptase Levels in a Severe Asthmatic Patient Undergoing SCIT for Birch: Implications for Monitoring and Personalized Treatment

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis